Comparative Pharmacology
Head-to-head clinical analysis: JENTADUETO XR versus SAXAGLIPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENTADUETO XR versus SAXAGLIPTIN.
JENTADUETO XR vs SAXAGLIPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENTADUETO XR combines linagliptin, a DPP-4 inhibitor that increases incretin levels (GLP-1, GIP) leading to glucose-dependent insulin secretion and decreased glucagon release, and metformin, an AMPK activator that decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and improves insulin sensitivity.
Saxagliptin is a selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), which prolongs the action of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
The usual starting dose of JENTADUETO XR (empagliflozin/metformin extended-release) is 5 mg/1000 mg orally once daily with the evening meal. Dose can be increased to a maximum of 12.5 mg/2000 mg once daily based on glycemic control and tolerability.
2.5 mg or 5 mg orally once daily irrespective of meals.
None Documented
None Documented
Clinical Note
moderateSaxagliptin + Gatifloxacin
"Saxagliptin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSaxagliptin + Rosoxacin
"Saxagliptin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSaxagliptin + Levofloxacin
"Saxagliptin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSaxagliptin + Trovafloxacin
"Saxagliptin may increase the hypoglycemic activities of Trovafloxacin."
Linagliptin: 12 h (terminal, steady-state) with once-daily dosing providing sustained DPP-4 inhibition. Metformin: 6.2 h (terminal elimination) in patients with normal renal function; prolonged in renal impairment, contraindicated if eGFR < 30 mL/min/1.73 m².
Terminal half-life: 2.5 hours; accounts for DPP-4 inhibition duration despite rapid clearance.
Linagliptin: ~90% excreted unchanged in feces via enterohepatic recycling, <5% renally eliminated. Metformin: ~90% eliminated unchanged in urine via glomerular filtration and tubular secretion, <10% in feces.
Renal (75% as unchanged drug and metabolites; 25% as unchanged drug in urine) and fecal (22% as metabolites).
Category C
Category A/B
DPP-4 Inhibitor / Biguanide Combination
DPP-4 Inhibitor